Drug Profile
Sibeprenlimab - Visterra
Alternative Names: VIS-649Latest Information Update: 22 Feb 2024
Price :
$50
*
At a glance
- Originator Visterra
- Class Monoclonal antibodies; Urologics
- Mechanism of Action B-cell maturation antigen antagonists; Transmembrane activator and CAML interactor protein inhibitors; Tumour necrosis factor ligand superfamily member 13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III IgA nephropathy
Most Recent Events
- 16 Feb 2024 Otsuka Pharmaceutical plans to submit the Biological Licensing Application to the US FDA and other global regulatory authorities for IgA-nephropathy
- 16 Feb 2024 Sibeprenlimab - Visterra receives Breakthrough Therapy status for IgA nephropathy in USA
- 28 Jan 2024 No recent reports of development identified for phase-I development in IgA-nephropathy(In volunteers) in Australia (SC, Injection)